Replies to post #241049 on Biotech Values

[DewDiligence]

My 2022 picks for the Silicon Investor Charity Contest are:

• ENTA 20%: Large position in my real portfolio.

• RVNC 20%: Ditto. (Fixing the manufacturing problem and resubmitting the Daxi BLA should be worth a nice gain even if FDA approval doesn’t come until 2023.)

• SPEX.SW 20%: Under-the-radar company resulting from the reverse-merger of (private) EnBiotix and POLN.SW. Has phase-3 program of inhaled antibiotic for CF patients. Plans to list on Nasdaq during 2022. (The symbol changed from POLN.SW to SPEX.SW at today’s open.)

• XENT 20%: Re-allocation vig; being acquired by MDT for cash.

• BMY 5%: Undervalued stock in my real portfolio.

• PFE 5%: Ditto. (Considerable upside even after 60% rise in 2021.)

• ASMB 5%: Well-funded and trading for only 65% of cash value! HBV program has been unimpressive, but they might get lucky.

• PRDS 5%: Protease inhibitor for COVID entering phase-1.

Thanks for asking.